AEB1102
Drugmodified human arginase I
Other names: Co-ArgI-PEG, Pegzilarginase
NCT Number: NCT03378531
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Looking for future studies?
Notify Me2 year and older
All sexes
Interventional
Phase 2
The Hospital for Sick Children, Toronto, Ontario, Canada
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
modified human arginase I
Other names: Co-ArgI-PEG, Pegzilarginase
Time frame: From start of study up to 262 weeks
Time frame: From start of study up to 262 weeks
Time frame: From start of study up to 240 weeks
Change in plasma arginine concentrations from study Baseline
Time frame: From start of study up to 240 weeks
Change in plasma argininic acid concentrations from study Baseline
Time frame: From start of study up to 240 weeks
Change in plasma guanidinoacetic acid concentrations from study Baseline
Time frame: From start of study up to 240 weeks
Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline
Time frame: From start of study up to 240 weeks
Change in plasma α-N-acetylarginine concentrations from study Baseline
Time frame: From start of study up to 262 weeks
Change in 6MWT distance from study Baseline
Time frame: From start of study up to 262 weeks
Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing.
Time frame: From start of study up to 262 weeks
Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping.
Time frame: From start of study up to 262 weeks
Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity.
Time frame: From start of study up to 262 weeks
Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance.
Time frame: From start of study up to 262 weeks
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.
Time frame: From start of study up to 262 weeks
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.
Time frame: From study start up to 262 weeks
Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management.
Time frame: From study start up to 262 weeks
Looking for future studies?
Notify MeImmedica Pharma AB
Industry
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03921541
Amino Acid Metabolism, Inborn Errors, Arginase I Deficiency
Rogers, Arkansas, United States
View Trial DetailsNCT02488044
Amino Acid Metabolism, Inborn Errors, Arginase I Deficiency
Stanford, California, United States
View Trial DetailsNCT03655223
17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT04612764
ARGI Deficiency, ASL Deficiency
Aurora, Colorado, United States
View Trial Details